AstraZeneca Projects Steady Growth with 2025 Results
AstraZeneca PLC has announced its financial results for the third quarter and first nine months of 2025, reiterating its total revenue and core EPS guidance for the full year. The company is poised to sustain growth through 2026 and is on track for its 2030 goals.
AstraZeneca PLC has released its financial results for the third quarter and the first nine months of 2025, affirming its revenue and core EPS forecasts for the year.
The pharmaceutical giant continues to demonstrate consistent growth with projections showing stability through 2026.
Positioned strategically, AstraZeneca aims to achieve its ambitious 2030 targets, promising sustained progress and development.
Advertisement
ALSO READ
-
Judges Rally for Fitness at the All India Badminton Championship 2025
-
FinnLAC Forum 2025 Charts Future of Financial Innovation in Latin America
-
Celebrating Southern Success: Evolving South India Business Excellence Award 2025
-
Bihar Elections 2025: A Historic and Decisive Battle Unfolds
-
Charcha 2025: Igniting Cross-Sector Conversations for a Resilient India
Google News